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Abstract
Background: There are 6.2 million children under the age of 18 years who have an asthma
diagnosis (Center for Disease Control and Prevention, 2017). Only 60% of children ages 7-17
years with persistent asthma maintain their prescribed inhaled corticosteroid (ICS) controller
medication regimen (Arnold, Bixenstine, Cheng, & Tschudy, 2018). The purpose of this paper is
to discuss a practice inquiry project that incorporated the implementation of an asthma
medication dosing chart to increase compliance in pediatric asthma patients.
Method: The quasi-experimental pretest-posttest design evaluated the daily use of a medication
dosing chart, which was to serve as a physical reminder for children and their families to take
their daily inhaled corticosteroid as prescribed. Emergency room visits, hospital admissions,
missed ICS doses, rescue inhaler and oral steroid use were measured to determine if increased
dosing compliance influenced how well the pediatric patient’s asthma is controlled.
Results: Of the pre-intervention group (n=27), only 13 attended the follow-up visit and
completed the post-intervention survey. There was statistical significance (p=.002) with missed
ICS doses, it decreased from an average of 1.7 missed doses per week to an average of .31 doses.
A decrease in ED visits (p=.226), decrease in hospitalizations (p=.393), and oral steroid courses
from (p=.730) were noted but not deemed statistically significant. Rescue inhaler use decreased
from an average of 1.89 times per week to 1.08 times (p=.254).
Conclusion: Having a decrease in the number of missed ICS doses per week is the most
significant measure that demonstrated improved compliance. While all other measures had
notable decreases, based on the small post-intervention sample size (n=13) there was not
statistical significance seen with improved compliance based on the use of the medication dosing
chart. Further studies on a larger scale over a longer period are recommended.
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Background and Significance
Problem Identification
As of 2017, there are 6.2 million children under age 18 years who have asthma which
makes this the most common chronic condition among the pediatric population (American Lung
Association, 2018; Center for Disease Control and Prevention, 2017). Medication adherence is a
common denominator for why children are hospitalized for asthma exacerbations. Only 60% of
children ages 7-17 years with persistent asthma maintain their prescribed inhaled corticosteroid
(ICS) controller medication regimen (Arnold, Bixenstine, Cheng, & Tschudy, 2018). Due to poor
medication adherence, asthma is the third-ranked cause for hospitalization in children under the
age of 15 years (Nurmagambetov, Kuwahara, & Garbe, 2017).
Context of Problem
Asthma is an obstructive pulmonary disease that makes it difficult to move air in and out
of the lungs (American Lung Association, 2018). In individuals with asthma, the airways are
always inflamed. Airway muscles become more swollen and constricted when in contact with
environmental triggers, making it more difficult to breathe (American Academy of Allergy,
Asthma, and Immunology, 2019). Asthma causes wheezing, chest tightness, increased mucus
production, and trouble breathing especially early or late in the day (American Academy of
Allergy, Asthma, and Immunology, 2019). When taken daily as prescribed, ICS controller
medications can inhibit the inflammatory process caused by asthma symptoms and decrease
chronic inflammation in the lungs over time. Beta-2 agonists, commonly referred to as rescue
medications are used during an exacerbation of symptoms or to pre-treat prior to exercise
(American Academy of Allergy, Asthma, and Immunology, 2019). Children with poor
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medication compliance often experience more asthma-related symptoms and are more likely to
need oral steroids, visit the emergency department, and/or be hospitalized due to their asthma
(CDC, 2018).
Scope of Problem
There are intentional and non-intentional barriers to asthma medication adherence in
children. Intentional barriers include illness perception, medication beliefs, and deliberately
choosing not to take the medications (Klok, Kaptein, & Brand, 2015). Non-intentional barriers
include family routine, child-raising issues, and social issues such as poverty (Klok et al., 2015).
Race, education and poverty levels severely effect asthma medication adherence in children
(Arnold et al., 2018). At Children’s Hospital of Michigan- Detroit, 35.5% of the children
admitted for asthma exacerbations reported to not having their asthma medications, specifically
their beta-2 agonist (Poowuttikul, Hart, Thomas, & Secord, 2017). Teenagers are most likely to
lack their asthma medication supplies at home (55.6%) compared to toddlers (~17%). Those with
severe persistent asthma (31.8%) were also more likely to be lacking their asthma medication
supplies (Poowuttikul et al., 2017). Understanding why children do not have their asthma
medications is a start to better address gaining control of their disease.
Consequences of Problem
Poor asthma control can cause severe and/or potential life-threatening exacerbations.
During an exacerbation, the airway can constrict to the point that other vital organs do not
receive the oxygen required to function properly (American Academy of Allergy, Asthma, and
Immunology, 2019). In 2013, only 54.5% of children were taking their asthma controller
medications as prescribed, a significant decrease over the previous decade (CDC, 2018).
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Between 2013 and 2016, of the 54% of children reported having at least one asthma exacerbation
during that time frame, 4.7% were hospitalized and 16.7% visited the emergency department
(ED) or urgent care (UC) for asthma-related symptoms (CDC, 2018). Younger children with
asthma (0-4 years) have higher rates of exacerbation, hospitalizations, and ED/UC visits often
due to their exclusive reliance on caregivers for their medication (CDC, 2018). Using the ED to
“manage” asthma versus attending routine follow-up appointment with a pediatric specialist or
their primary care provider (PCP) is another known issue that contributes to poor asthma control
(Kwok et al., 2018). Developmentally, children ages 6-11 years are learning to think in concrete
ways. During this stage of cognitive development, school-age children learn to combine, order,
separate, and transform objects and actions (Cincinnati Children's , 2017). It is not until
adolescence that children are able to process formal logical operations such as the ability to think
abstractly and reason through problems which can make having the sole responsibility of
managing a chronic disease difficult in the younger age groups (Cincinnati Children's , 2017).
Children ages 6-11 years have not cognitively developed in a way that allows them to understand
the importance of medication compliance and management on their own.
Evidence-Based Intervention
A visual tool was developed for use by the families of medically diagnosed, asthma
patients age 6-11 years. The tool will be introduced and distributed to children with asthma
during routine, follow-up visits at University of Louisville, Pediatric Pulmonology Clinic. On a
laminated sheet there will be boxes labeled with each day of the week, Sunday through Saturday.
The goal is for a family member, or the child (if age appropriate), to “check off” the daily boxes
when they take their medications as prescribed each day, with the provided dry-erase marker.
There will be a set of boxes on the bottom left of the tool with each box representing a week, so
10

that each week can be “checked off” during the three to four months in between their scheduled,
follow-up appointments. The family is encouraged to hang the tool somewhere in plain view, so
it isn’t overlooked. Upon their return for their follow-up visit, within the 3-4 month time frame,
it will be determined if the chart was helpful for the child or family in remembering to administer
asthma medications, if the medications were administered as prescribed, and whether they felt
their child’s overall health had improved due to increased compliance.
Purpose of Project
The purpose of this project was to evaluate the use of a medication dosing chart in
increasing the daily use of their ICS controller medication as prescribed to children with asthma,
thus reducing the need for oral steroids, usage of rescue medications, hospitalizations and
ED/UC visits.
Theoretical Framework
Albert Bandura’s self-efficacy theory is pertinent to asthma compliance. Bandura (1994)
determines that perceived self-efficacy is one’s belief about their capabilities to perform tasks
that influence and affect their life events. If an individual has a high assurance of their abilities,
they will take on the difficult task with a goal of mastering it (Bandura, 1994). Those with low
assurance perceive difficult tasks as personal threats, have low aspirations, and weak
commitments to their goals (Bandura, 1994). The motivational processes of the self-efficacy
theory help individuals form beliefs about what they can do and anticipate outcomes of future
actions (Bandura, 1994). It is important to provide education and resources to children and
families that are seeing asthma as difficult to manage so they can develop a high assurance for
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the disease and want to manage it well. This theoretical framework determined the need and
guided the development of the asthma medication compliance chart.
Literature Review
Being one of the most common chronic conditions in children, asthma has a significant
impact on this vulnerable population. Asthma contributes to millions of lost school days each
year and is the third leading cause of hospitalization in the younger population (American Lung
Association, 2019). Poor asthma medication compliance often contributes to missed school days
and hospitalizations. There are many reasons attributing to poor management and poor
compliance. Intentional and non-intentional barriers to asthma medication regimens result in
emergency department (ED) visits for asthma exacerbations or asthma-related problems.
Evidence shows that non-Hispanic black families living in poverty have the highest incidence of
asthma-related problems in children due to poor medication adherence (Arnold, Bixenstine,
Cheng, & Tschudy, 2018, Pertzborn et al., 2018, & Kwok et al., 2018). Poverty is one nonintentional barriers families face when it comes to poorly managed diseases. Family routine,
child-rearing issues, and limited access to education are additional non-intentional barriers (Klok
et al., 2015). Illness perception, medication beliefs, and deliberately choosing not to take
medication are examples of intentional barriers caregivers of children with asthma should be
cognizant of when learning to care for their child’s disease (Klok, Kaptein, & Brand, 2015).
Arnold et al., 2018 found that forgetfulness was another barrier to adequately managing a child’s
asthma. The children with asthma are not placing blame on others for forgetting their
medications, but rather their caregivers blame the child for forgetting their medications (Arnold
et al., 2018). The inappropriate lack of responsibility by caregivers is putting children at risk for
increased asthma exacerbations and ED visits.
12

There is evidence that caregivers are interested in learning about how controller
medications work, when to initiate rescue medications based on known triggers, and the safety
profile of each asthma medication (Kwok et al., 2018). Caregivers and children should equally
understand their roles in managing asthma, so all parties are aware of triggers, when to use
appropriate medications, and when to seek help. The need for increased awareness of patientcentered communication by physicians is key in helping caregivers and their children learn these
concepts to help better manage the disease (Klok et al., 2015).
School-age children need a sense of purpose; help them by giving them goals to use their
energy toward achievement (American Academy of Pediatrics [AAP], 2009). During this stage
of life, it is equally important for children with asthma to develop a personal competence and
sense of pride (AAP, 2009). Allowing them to begin participating in managing their disease with
the help of their caregivers can allow them to develop their sense of purpose, competence, and
pride. Gaining more independence at this age is also especially important, as school-age children
are spending more time away from their parents (AAP, 2009). The average age of asthma
diagnosis has dropped to 2.6 years-old, which allows many children several years of learning
about their disease and time to understand how its managed (Radhakrishnan et al., 2014).
School-age children should be engaging in shared asthma management responsibility with their
caregivers, especially during times they are not at home (Sonney, Segrin, & Kolstad, 2018).
Family dynamics should be considered when discussing shared asthma management. Shared
management can assist the child in the development and feeling a sense of inclusion and
accomplishment with their care (Sonney et al., 2018).
There are several different mediums used to manage asthma medication adherence in
young patient populations. Adult studies have been a guide to learning barriers of asthma control
13

in the pediatric population (Anderson III & Szefler, 2015). Electronic Monitoring Devices
(EMD) have gained popularity over the last few years for achieving disease control and
medication adherence (Anderson III & Szefler, 2015). While this type of monitoring system
gives the impression of having few flaws, there are several to consider. EMDs have associated
costs, technology needs, significant patient education, and potential device failure (Anderson III
& Szefler, 2015). EMDs can also provide reminders to patients to take their medications and
provide information about upcoming appointments (Arnold et al., 2018). Reminders about
upcoming appointments can be beneficial for families who have a busy and/or difficult family
routine. Electronic monitoring is considered a “gold standard” for disease control but cost and
access is a major concern for some families (Boutopoulou, Koumpagiot, Matziou, Priftis, &
Douros, 2018). Even during the technology boom the world is experiencing, not every individual
has access to a smart phone (Statista, 2019). It is important to consider ease of access, ease of
use, and cost when providing a “device” designed to help with disease control and medication
adherence. Diary cards or self-reporting devices provide a way to subjectively measure data; they
are inexpensive, convenient, relatively unobtrusive, and should not suffer from technologic
difficulties (Anderson III & Szefler, 2015 & Boutopoulou et al., 2018). However, like EMDs,
self-reporting devices come with their own set of flaws. Accuracy and adherence can
demonstrate that this device is not necessarily the best choice for each family (Boutopoulou et
al., 2018). If the family is already having difficulty adhering to their current asthma medication
regimen, they may not want to adhere to a diary card or self-reporting device in addition to the
medication which could then lead to filling out false information to give the impression they
participated (Boutopoulou et al., 2018). Self-reporting is an excellent medium to incorporate use
in school-age children. The caregiver or parent can support shared management with the child to
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fulfill everyone’s needs. The child may be motivated to see success on their diary card, and feel
like they have achieved a goal each time they “check” a box for taking a medication or
completing another week of adhering to their regimen (AAP, 2009). The caregivers will play an
active role in monitoring the child’s use of the diary card to ensure medications are taken as
prescribed while allowing the child to participate in “checking off” boxes. The advantages of
using self-reporting devices in the school-age population outweighs the disadvantages compared
to EMDs (Boutopoulou et al., 2018).
There are pros and cons for each monitoring device and the literature shows that a more
targeted, personalized method of assessment of disease control and medication adherence are
required to achieve adequate management (Boutopoulou et al., 2018). The provider-chosen
monitoring device is advantageous for a caregiver and their child to help gain better control of
their child’s asthma. Knowing the needs of any targeted population is significant for achieving
success.
Project Design
The design used for this project was a quasi-experimental pretest-posttest research
design. One group will be assessed on two separate occasions. This type of study design works
best with projects in which interventions are implemented over longer periods of time and uses
pretest and posttest to assess the intervention.
Project Methods
Agency Description
University of Louisville Physicians (ULP) pediatric pulmonology office is the location in
which this project was implemented. This facility is in downtown Louisville inside the brand15

new Novak Center for Children’s Health, where all other University of Louisville pediatric
specialty offices are also located. ULP Pediatric Pulmonology is made up of four physicians, one
nurse practitioner, two respiratory therapists, and one medical assistant. This group of healthcare
professionals uses practice recommendations from the American Board of Pediatrics, American
Academy of Pediatrics, and the American Thoracic Society to provide comprehensive care to the
various lung and respiratory diseases found in the pediatric population (University of Louisville
Physicians Pediatric Pulmonology, 2013).
Setting
The implementation of the asthma medication dosing chart took place in the exam rooms
at the ULP Pediatric Pulmonology office during the study participant’s appointment time. ULP
Pediatric Pulmonology is located on the fifth floor in the Novak Center for Children’s Health in
downtown Louisville, KY.
Sample
The sample population for the project was children ages 6-11 years living in Kentucky,
with an asthma diagnosis, and a prescribed daily inhaled corticosteroid (ICS). Participants were
evaluated for inclusion and exclusion criteria and recruited during their routine, follow-up
appointment where asthma medication compliance is evaluated and discussed. Children meeting
inclusion criteria and interested in participating were identified. The project was presented, and
parent consent/child assent was obtained prior to enrollment in the study.
Inclusion and Exclusion Criteria
Inclusion criteria for the participants included being between the ages of 6-11 years, living
in the state of Kentucky, having an asthma diagnosis, and be prescribed an inhaled corticosteroid.
16

Exclusion criteria consisted of being younger than 6 years and older than 11 years at time of
recruitment, living outside of Kentucky, not having a prescribed ICS controller medication, and
requirement of an interpreter. Missed ICS doses, rescue inhaler usage, ED visits, hospitalizations,
and oral steroid use were the variables measured on the survey
Congruence of DNP Project
This DNP project is in congruence with ULP Pediatric Pulmonology’s mission, goal, and
strategic plan. Their mission is to “help patients breathe more easily and to deliver exceptional,
state-of-the-art medical care” and their goal is to “improve quality of life, as well as preserving
and restoring respiratory health” (University of Louisville Physicians Pediatric Pulmonology,
2013). The project goal was to evaluate the use of a dosing tool to increase medication
compliance in children with asthma who use a daily ICS for maintenance control of their asthma.
Tool effectiveness is measured in number of exacerbations requiring ED/UC visits,
hospitalizations, and the need for oral steroids in the interim between follow-up visits. This
activity aligns with ULP’s goal of improving quality of life and preserving lung health in the
pediatric population and their mission of helping patients breathe easier (University of Louisville
Physicians Pediatric Pulmonology, 2013). Creating a plan to assist medication compliance may
contribute to a reduction in exacerbations, ED visits/hospital admissions, or need for oral steroid
use on a regular basis.
Stakeholders
The stakeholders involved in the implementation of this project are children with asthma,
prescribed an ICS controller medication. The participant’s parents/caregivers were also an
extremely important stakeholder because the participants are too young to assume full
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responsibility with their care and participation in the study. Parent/caregiver involvement was
essential for the success of their children. Other important stakeholders were the nurse
practitioner and respiratory therapists who were necessary to identify eligible participants, access
data, and provide expert care and information on asthma throughout the recruitment,
implementation, and evaluation process. The healthcare professionals in the clinic were more
familiar with the patients and families typically seen 3-4 times per year and were able to guide
the project. Having the involvement of these key stakeholders was essential to collecting
accurate data in a timely manner and the ability to provide the participants and families with an
alternative to assist in their current medication dosing compliance.
Facilitators and Barriers
Some of the facilitators encountered within the agency was the availability of a colored
guide of all respiratory medications, available in each exam room to inquire about the patient’s
knowledge of which medications are taken and whether they can differentiate between their ICS
controller and their beta-2 agonist, rescue inhalers. The nurse practitioner also had access to
medication samples for patients having issues acquiring or purchasing their medications. Having
immediate access to the pulmonary function testing results during the initial visit and the followup visit helped measure how the patient’s lung function changed over the four-month study.
Being familiar with the office staff and other healthcare professionals helped facilitate patient
recruitment, enrollment, data collection, and a follow-up data collection at the end of the study.
Barriers encountered with the implementation of the project included not having direct
access to patient clinic charts, contact information, and the need to have the office personnel
determine eligible enrollees. Other barriers included some participants’ inability to maintain use
of the given materials. Participants failing to follow-up as scheduled was an additional barrier for
18

follow-up data collection at the end of the study. The limited number of eligible participants due
to time constraints and unqualified participants was an additional barrier impacting overall
enrollment into the study.
Description of Project
The asthma medication dosing chart (Appendix C) was created to allow participants and
families to physically see when and how often medications were being taken. The horizontal
chart has a row of seven boxes, labeled for each day of the week, that are designed to be
“checked off” each day the ICS is taken as prescribed, with the provided dry erase marker. The
daily boxes were designed to be wiped off and restarted at the end of each week. Below the daily
row to the left is the section of “weeks completed”. This section was designed to help families
keep track of how many weeks were tracked between appointments. These boxes were also
designed to be “checked off” with the provided dry erase marker. To the right of the “weeks
completed” section is the “rescue inhaler used” section. This section is to allow participants and
families to make tally marks showing how often the rescue inhaler was needed between
appointment times. It is not designed to be wiped off and restarted each week. A silicone pen
holder was applied to the laminated chart in hopes of helping the provided dry erase marker to
stay with the chart during the several months between appointments.
The pre- and post-intervention asthma questionnaire (see Appendix B) was completed at
the initial visit after legal documents were signed. This questionnaire collected the specific data
that was used to analyze the helpfulness of the asthma medication dosing chart. At the final
appointment, the questionnaire was supplied again with the exact same questions to determine if
ED visits, steroid use, rescue inhaler use, and number of times forgetting to take the ICS on a
weekly basis differed from the initial appointment.
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Procedure
IRB Approval
Obtaining IRB approval for this project occurred in two stages. Initial approval came
from the University of Kentucky IRB. Further approval from the University of Louisville IRB
was needed due to the location of project implementation. The project implementation was
initiated following approval from both institutions.
Sample
A convenience sample of twenty-seven children ages 6-11 years with an asthma
diagnosis and a prescribed daily inhaled corticosteroid was obtained at random based on the
clinical schedule of the nurse practitioner and availability of the PI to collect necessary data.
Initially, a manual search was done on the individual patients on the nurse practitioner’s schedule
by the nurse practitioner. The process of the manual search began with patients selected by age,
then their home address (must live in Kentucky) was verified, followed by asthma diagnosis, and
ICS prescription on their medication list. Individuals that met the inclusion criteria were given a
flyer (Appendix D) by the nurse practitioner at the beginning of their appointment. At the
conclusion of the appointment, the nurse practitioner inquired the patient and family about
interest and willingness to participate in the study. If willing to participate, the nurse practitioner
informed the PI to enter the exam room, and provide a brief, detailed description of the study and
its purpose. If the patient and family were still interested in participating in the study, then the
legal documents to obtain informed consent, assent, and HIPAA guidelines were signed and
dated by the primary investigator and participant and their family.
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Measures and Instruments
See Appendices A, B, and C. The instrument used to measure the demographics, ICS and
rescue inhaler information, and asthma diagnosis was obtained from chart review of the study
participant’s medical records. The asthma medication survey created was administered preintervention and post-intervention to collect information on the outcomes of ED visits,
hospitalizations, oral steroid need, daily ICS use, and rescue inhaler use before and after
medication dosing chart usage. The asthma medication dosing chart and pre/post questionnaires
were reviewed by an asthma expert, the nurse practitioner working for ULP Pediatric
Pulmonology, for content validity. These tools were not in existence prior and were created
specifically for this practice inquiry project. There is not any validity or reliability data
associated with these tools at this time.
Implementation
Implementation of the asthma medication-dosing chart began once informed consent,
assent, and HIPAA documents were signed and dated by all parties. The parent/legal guardian
was provided with copies of consent documents to participate in the study. Assent was also
obtained from each child after informing them of how they were expected to participate and with
their agreeance to enroll in the study. Parents and legal guardians were also presented with a
HIPAA document explaining that their child’s personal health information would not be used or
be identifiable in the study. The child’s age, FEV1 results, and answers to the asthma
questionnaire were the only information being used for the study and would not be able to be
tracked back to the individual participants. After each of the three consents were signed and
dated, the participant and the parent/guardian were given the asthma medication dosing chart.
They were shown how to “track” their daily ICS use by using the dry erase marker provided with
21

the chart. After the participant’s ICS was taken each day, they were to put a “check” or “X” in
the correlating day of the week box. Once the week was complete, they were to erase and start
over, while also putting a check in the “weeks completed” box below. The participants were
instructed to continue repeating this weekly until they returned for their next appointment. They
were also informed to put tally marks under the “rescue inhaler used” section so families could
see a general idea of how much their child was needing extra help. Instructions were also
reviewed with the parent/legal guardian as they still have a significant obligation to remind the
child to take their medication.
Results
A total of 27 patients met the inclusion criteria for this study within the project timeline
and were enrolled in the study. Pre-intervention survey was completed, and each participant
received the asthma medication dosing chart with a dry erase marker. A total of 13 participants
attended their follow-up appointment and completed the post-intervention survey.
Of the 27 pre-intervention participants (Appendix E, Table 1), there were 8 (29.6%) that
required at least one ED visit and one participant visiting the ED 10 times (12.5%) for asthmarelated issues. Post-intervention, there was only one participant (7.7%) that required two ED
visits. Using Chi-Square and Fisher’s Exact Testing, a p value of p=.226 was obtained and
determines there is not a statistically significant difference in ED visits with the use of the
asthma medication chart.
Out of the 27 pre-intervention participants, there were six (22.2%) that required
hospitalizations due to an exacerbation. Each participant only required one hospitalization for
asthma complications in a four-month period. There was only one (7.7%) post-intervention
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participant that required one hospitalization on one occasion. With the Chi Square and Fisher’s
Exact Testing, a p value of p=.393 was obtained and shows that there is not a statistically
significant difference in hospitalizations based on the use of the asthma medication chart.
Oral steroid use for the 27 pre-intervention patients was 40.7% with 11 participants
needing steroids prior to receiving the medication chart. The number of steroid courses needed
for these participants ranged from one to five. After the chart was implemented, there were only
four (30.8%) participants who required oral steroids for an asthma exacerbation. The postintervention steroid courses needed ranged from one to two which shows a decrease in need. A p
value of p=.730 was obtained and shows there is no statistical significance related to oral steroid
use after the asthma medication chart was implemented. Chi Square and Fisher’s Exact Testing
were also utilized for this analysis.
The mean number of times the participants missed their inhaled corticosteroid preintervention was 1.7 times per week with a standard deviation of 1.938. Post-intervention, the
participants improved their missed ICS doses to .31 times per week and a standard deviation of
.63. There was improvement in the doses of ICS missed per week after the intervention was
implemented into daily routine. With a p value of p=.002 it shows this data is statistically
significant using Levene’s Test for Equality of Variances where equal variances were not
assumed.
Rescue inhaler use had a mean of 1.89 times per week pre-intervention with a standard
deviation of 2.1. Post-intervention, the rescue inhaler usage decreased to 1.08 times per week
with a standard deviation of 2.019. The number of times the rescue inhaler was needed postintervention was half of what was needed pre-intervention but is not considered statistically
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significant with p=.254 using Levene’s Test for Equality of Variances where equal variances
were assumed.
Additional data for another variable was collected for the interest of the project. FEV1%
(forced expiratory volume) is indicative of lung function and was monitored to determine if there
was any improvement related to using the chart. This variable specifically measures how much
air can be exhaled in one second after a significant inhalation (Stanojevic, et al., 2008). Normal
reference range for FEV1 is considered to be between 70-79% (Stanojevic, et al., 2008). While
FEV1% was not a specific variable being analyzed to determine the efficacy of the asthma
medication chart for the purpose of this project, it was collected to see if there was an overall
increase in lung function with improved medication compliance. Pre-intervention, the mean
FEV1% for all participants was 82.11%. After the chart was implemented, the mean FEV1%
increased to 86.9%. There was a small improvement in lung function noted but according to
Levene’s Test for Equality of Variances when variances were not assumed it showed p=.327
which determines this data is not statistically significant.
Lastly, on the post-intervention survey, a question was asked about whether the asthma
medication chart was helpful. This question was asked to get a consensus of how the participants
and their families felt about implementing the chart into their daily routine. Of the 13 postintervention participants, 11 (84.6%) participants thought the medication chart was helpful while
the remaining two (15.4%) did not think it was helpful but were “already compliant” and
“already had a routine”.
SPSS Version 25 and Microsoft Excel were used to analyze, and display collected data.
See tables in Appendix E.
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Discussion
The goal of this project was to help improve medication compliance and lung function in
pediatric asthma patients who take a daily ICS by decreasing missed medication doses; lowering
the need for rescue inhaler use; decreasing ED visits, hospitalizations, and need for oral steroids
by implementing a medication chart into their daily routine.
The results came out as relatively expected. Each measure saw improvement or decrease
where warranted but after analysis, most measures were not shown to be statistically significant
except for missed ICS doses per week. Ultimately, decreasing the number of missed ICS doses
per week is the most important measure where change is needed in order to decrease all other
measures subsequently. By adhering to the prescribed medication regimen, participants decrease
their likelihood of needing to visit the ED, be hospitalized, and require a course of oral steroids.
Implications
This study could be used in future practice as it showed to have a statistically significant
effect on the number of missed ICS doses per week by the pediatric asthma patients. By
decreasing missed doses of a participant’s ICS, they are less likely to need to visit the ED, be
hospitalized, and require oral steroids. While these measures (ED visits, hospitalizations, and
oral steroids) did not present statistically significant data, there was a notable decrease in
numbers comparing pre-intervention to post-intervention measures. More in depth research with
closer participant follow-up is recommended on a larger scale to determine if the asthma
medication chart could have a more successful impact on medication compliance while
improving lung function.
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Limitations
There were several limitations to this project. The participants were not assigned an
identifier during the pre-intervention appointment which would allow for easier pairing of before
and after results during the post-intervention appointment. Due to not having an identifier, it was
difficult to pair pre-intervention numbers with post-intervention numbers demonstrating
individual evaluation of the use of the asthma medication dosing chart on ED visits,
hospitalizations, oral steroids use, and/or missed ICS doses.
The participant’s asthma diagnoses, gender, and ethnicity were not identified which could
indicate the severity of each participant’s asthma disease. The severity of asthma could likely
influence the number of ED visits, hospitalizations, and oral steroid courses needed overall
(Poowuttikul et al., 2017). In addition, it would have been beneficial to identify which ICS each
participant was administering related to their asthma diagnosis. If one participant is requiring a
stronger medication or dosing of several asthma-related medications, their degree of control may
impact the outcomes related to ED visits, hospitalizations, and oral steroid courses needed. These
outcomes may not be influenced by use of the asthma medication dosing chart use, but rather
their disease severity.
Not only are specific diagnoses important to include for each participant, it should be
mentioned that when their FEV1 percentages were measured at each appointment, there were
several variables to be noted that influenced initial measurements. During pre-and postintervention appointments, some participants were amid an undiagnosed exacerbation while
some were actively taking oral steroids. These variables, exacerbations and steroids, affect
FEV1% both negatively and positively, respectively. This provided inaccurate data at the time of
the appointment so without doing a more in-depth chart review on every participant to determine
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their average over the previous year, it is difficult to say which participants truly improved their
lung function. This is one of the reasons why there was not a significant emphasis put on the
FEV1% measured and why they were analyzed as a more general variable to see an overall
improvement or decline.
Another limitation noted for this project was having participant’s which have a history of
being non-compliant with appointment attendance. For the interest of this project, non-compliant
patients were not excluded as there was a possibility, they might be more compliant with
implementation of the asthma medication dosing chart. The medication dosing chart was
designed to encourage and assist with compliance and may assist those who struggle with
medication dosing compliance on a regular basis. During chart review to determine participant
eligibility, reviewing past appointment history may have assisted with identification of
participants less likely to complete the study. If the traditionally non-compliant participant
presented on a day of data collection and met inclusion criteria, they were still approached about
participating in the study. This may have affected the number of follow-up participants. The
sample size of (n=27) was affected by many who fulfilled inclusion criteria not showing up for
their appointment. With more time for data collection, it is possible a larger sample size of
patients could have been collected which may have yielded more accurate results.
Another important limitation to be discussed is that the primary investigator did not have
contact with any participants or families during the four-month follow up window which could
have allowed for more engagement between the participant and the intervention and potential for
more post-intervention surveys to be completed.
Lastly, as a comment per one of the post-intervention surveys, one participant stated
“[his] marker dried out”. This was a limitation noted prior to the start of the project but with few
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resource options available, it was the most cost effective and best overall option to ensure the
medication charts were able to be re-used over a 4-month period.
Conclusion
The goal for this project was to decrease the number of ED visits, hospitalizations, oral
steroid courses, missed ICS doses, and the need for excess rescue inhaler use in pediatric asthma
patients by implementing an asthma medication chart to assist with compliance. While the data
from this project did not identify many statistically significant changes, it is possible that if this
project were carried out on a larger scale over a longer period, findings could have differed. Most
importantly, missed ICS doses showed to have a statistically significant association with use of
the asthma medication chart and could therefore subsequently decrease the need for ED visits,
hospitalizations, oral steroid and rescue inhaler usage which would ultimately improve lung
function for pediatric asthma patients. Despite an overall decrease in all measures, a larger postintervention sample size would be beneficial to validate the data collected. Further studies are
needed on a larger scale to improve post-intervention sample size.
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List of Tables
Table 1. Percentage of ED visits, hospitalizations, and oral steroids courses

ED visit
Yes
No
Hospitalization
Yes
No
Oral Steroids
Yes
No

Pre-intervention
(n=27)
n (%)

Post-intervention
(n=13)
n (%)

p

8 (29.6%)
19 (70.4%)

1 (7.7%)
12 (92.3%)

p=.226

6 (22.2%)
21 (77.8%)

1 (7.7%)
12 (92.3%)

p=.393

11(40.7%)
16 (59.3)

4 (30.8%)
9 (69.2%)

p=.730

Table 2. Average number of missed ICS and rescue inhaler doses

Missed ICS

Rescue Use

Time

N

Mean

Pre-intervention

27

1.70

Post-intervention

13

.31

Pre-intervention

27

1.89

Post-intervention

13

1.08

Table 3. Average FEV 1%

FEV 1%

Time

N

Mean

Pre-intervention

27

82.11

Post-intervention

13

86.92
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p

p=.327

p

p=.002

p=.254

Appendix A. Measures and Instruments
Measures

Description

Level of
Measurement

Data Source

Demographics
Age

Age in years

Interval/Ratio

Medical
Records

Diagnosis/Medication
Information
Severity of Asthma

Mild, moderate, severe persistent Nominal
asthma diagnosis
Specific ICS prescribed to
Nominal
patient
Specific rescue inhaler
Nominal
prescribed to patient

Medical
Records
Medical
Records
Medical
Records

How often patient/family
remember to take daily ICS per
month

Interval/Ratio

Rescue Inhaler use

Number of times rescue inhaler
used over a 4-month period

Interval/Ratio

Hospital Admissions

Number of times patient was
admitted to hospital for
breathing problems during 4month period

Interval/Ratio

Asthma
medication
pre and postintervention
survey
Asthma
medication
pre and postintervention
survey
Asthma
medication
pre and postintervention
survey
Asthma
mediation
pre and postintervention
survey
Asthma
medication
pre and postintervention
survey
Medical
Records

Inhaled Corticosteroid
(ICS)
Rescue Inhaler
Outcome
Daily ICS use

Emergency Department Number of times patient visited
visits
ED during 4-month period for
breathing problems

Interval/Ratio

Oral steroid needs

Number of times patient needed
oral steroids in a 4-month period

Interval/Ratio

Pulmonary Function
tests (PFT)

Whether PFTs were improved,
decreased, or stayed the same
from initial appointment to final
appointment.

Nominal
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Usefulness of the
asthma medication
chart

Whether or not the asthma
medication chart was useful for
helping patients remember to
take their daily ICS

34

Nominal

Asthma
medication
postintervention
survey

Appendix B. Asthma Survey
1.

How many days do you use your inhaled corticosteroid per week? _______

2.

How many times have you needed to use your rescue inhaler in the last week? ______

3.

Have you had to visit the Emergency Department for breathing problems over the last 4
months? Yes or No
a.

4.

Have you had to be hospitalized for breathing problems over the last 4 months? Yes or
No
a.

5.

If yes, how many times? ______

Have you needed oral steroids for breathing problems over the last 4 months? Yes or
No
a.

6.

If yes, how many times? ______

If yes, how many times? ______

*Post-survey only* Did you feel the medication chart was helpful for remembering to
take your inhaled corticosteroid daily? Yes or No

Comments:
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
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Appendix C. Asthma Medication Chart

Sunday

Monday

Tuesday

Wednesday Thursday Friday

Saturday

*Inhaled
Corticosteroid
name &
dosage*

Weeks completed

Rescue Inhaler Used
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Appendix D. Recruitment Flyer
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